Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 

HOME >> API >> API List1 >> Desmopressin Monoacetate >> Pharmalogy

PHARMALOGY
Desmopressin Monoacetate CAS Number 62288-83-9

Desmopressin Monoacetate Tablets contain as active substance, desmopressin acetate, a synthetic analogue of the natural hormone arginine vasopressin.

Central Diabetes Insipidus: Dose response studies in patients with diabetes insipidus have demonstrated that oral doses of 0.025 mg to 0.4 mg produced clinically significant antidiuretic effects. In most patients, doses of 0.1 mg to 0.2 mg produced optimal antidiuretic effects lasting up to eight hours. With doses of 0.4 mg, antidiuretic effects were observed for up to 12 hours; measurements beyond 12 hours were not recorded. Increasing oral doses produced dose dependent increases in the plasma levels of Desmopressin Monoacetate
The bioavailability of Desmopressin Monoacetate oral tablets is about 5% compared to intranasal Desmopressin Monoacetate, and about 0.16% compared to intravenous Desmopressin Monoacetate. The time to reach maximum plasma Desmopressin Monoacetate levels ranged from 0.9 to 1.5 hours following oral or intranasal administration, respectively. Following administration of Desmopressin Monoacetate Tablets, the onset of antidiuretic effect occurs at around 1 hour, and it reaches a maximum at about 4 to 7 hours based on the measurement of increased urine osmolality.he use of Desmopressin Monoacetate Tablets in patients with an established diagnosis will result in a reduction in urinary output with an accompanying increase in urine osmolality. These effects usually will allow resumption of a more normal life style, with a decrease in urinary frequency and nocturia.There are reports of an occasional change in response to the intranasal formulations of Desmopressin Monoacetate (Desmopressin Monoacetate Nasal Spray and Desmopressin Monoacetate Rhinal Tube). Usually, the change occurred over a period of time greater than six months. This change may be due to decreased responsiveness, or to shortened duration of effect. There is no evidence that this effect is due to the development of binding antibodies, but may be due to a local inactivation of the peptide. No lessening of effect was observed in the 46 patients who were treated with Desmopressin Monoacetate Tablets for 12 to 44 months and no serum antibodies to desmopressin were detected.The change in structure of arginine vasopressin to desmopressin acetate resulted in less vasopressor activity and decreased action on visceral smooth muscle relative to enhanced antidiuretic activity. Consequently, clinically effective antidiuretic doses are usually below the threshold for effects on vascular or visceral smooth muscle. In the four long-term studies of Desmopressin Monoacetate Tablets, no increases in blood pressure in 46 patients receiving Desmopressin Monoacetate Tablets for periods of 12 to 44 months were reported.

Information Associated with Product:
DRUG DESCRIPTION DOSAGE SIDE EFFECTS PRECAUTIONS INTERACTION PHARMALOGY >> CONSUMER INFORMATION
PDF DOWNLOAD	WORD DOCUMENT
Product Enquiry Product Quotation Sample Request Place Your Order

Api Manufacturing At Taj

Acamprosate Calcium

Clomipramine Hcl

Alendronate Sodium

Clonazepam

Amitriptyline

Clopidogrel Bisulfate

Anastrozole

Danazol

Atomoxetine Hcl

Desloratadine

Balsalazide

Desmopressin Monoacetate

Bicalutamide

Divalproex Sodium

Budesonide

Dobutamine Hcl

Bupropion Hcl

Donepezil

Calcitonin

Dothiepin Hcl

Capecitabine

Entacapone

Carbamazepine

Eptifibatide

Carboplatin

Escitalopram HBr

Carisoprodol

Eszopiclone

Carvedilol

Finasteride

Cefuroxime Axetil

Flurbiprofen

Cisplatin

Fluticasone Propionate

Citalopram Hbr

Fluvoxamine Maleate

Fosphenytoin Sodium

Investor Relations    Feedback     Contact Worldwide    Sitemap